Fritextsökning
Innehållstyper
-
USA:s regering skrotar vaccinavtal med Moderna
Trumpadministrationen har avbrutit ett kontrakt som tilldelats Moderna för den sena utvecklingsfasen av ett fågelinfluensavaccin för människor, samt rätten att ...
-
Scientific Solutions
-
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
Clinical trials and precision health are emphasised as key areas in the new national life science strategy.
-
Cytel Sweden
-
Zelmic
-
A+ Science AB
-
Johan Pehrson takes over the responsibility for research policy in Sweden
The Liberals' party leader Johan Pehrson takes over the assignment as Minister for Education. This was announced by Prime Minister Ulf Kristersson (M) on Tuesday last week.
-
Roche’s Genentech terminates licencing deal with Norwegian biotech
Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.
-
A small thing that can solve your problems
If you are in need of a compact valve. Look no further! We have the VOVK
-
GSK acquires oncology research company
GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What w...
-
Higher throughput in less time
Do you want to automate your quality processes, shorten inspection times and increase your throughput? Gain inspiration from the experience of the medical techn...
-
19 medicines in Sweden are under investigation in a major EMA inquiry
19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Among them are medicines for HIV, epilepsy, cancer and Parkinson’s, which may be withdrawn...
-
Nordic Regulatory experts: Improving biotech chances of Succ
Why is it that so many biotech companies fail? And what are the tools needed to change that fact?
-
"Unclear proposal from the EU Commission on how to solve the MDR challenges"
Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the avail...
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
-
Kennedy stoppar bidrag till vaccinalliansen Gavi
USA kommer inte längre ge ekonomiskt stöd till Gavi förrän den globala vaccinalliansen ”återvunnit allmänhetens förtroende”. Det meddelar USA:s hälsominister Ro...
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...
-
One last chance to register for the premier metrology event in 2024
ZEISS QUALITY INNOVATION SUMMIT.
-
ZEISS O-INSPECT duo: The multifunctional measuring machine
ZEISS O-INSPECT duo combines advanced microscopy and metrology for impressive measurement accuracy.
-
Svensk obesitaskandidat visade lovande resultat – ”Kan få stor betydelse”
Tabletten ska främja viktminskning utan att påverka aptit eller muskelmassa. Resultaten är lovande, enligt en klinisk fas I-studie från Karolinska institutet oc...
-
Neanderthal gene variants may cause Viking disease
A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...